Peptide Lab HQ Research Guide
BPC-157 &
TB-500 Blend
A research-focused compound profile covering BPC-157 and TB-500 blend identity, gastric peptide and thymosin beta-4 pathway research, tissue-response models, tendon and ligament research, muscle and wound-healing research context, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | BPC-157 & TB-500 Blend |
|---|---|
| Common Research Names | BPC-157 / TB-500 blend, BPC-TB blend, tissue-response peptide blend, recovery-model peptide blend |
| Compound Type | Dual-peptide research blend / tissue-response research compound |
| Common Blend Format | Often prepared as a 1:1 mass-ratio blend, such as 10 mg BPC-157 + 10 mg TB-500 for 20 mg total blend. Verify final vial strength against supplier COA. |
| Component 1 | BPC-157 / Body Protection Compound 157 / stable gastric pentadecapeptide |
| BPC-157 Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| BPC-157 Short Sequence | GEPPPGKPADDAGLV |
| BPC-157 CAS Number | 137525-51-0; verify against supplier COA |
| BPC-157 Molecular Formula | C₆₂H₉₈N₁₆O₂₂; verify against supplier COA |
| BPC-157 Molecular Weight | Approximately 1419.56 g/mol; verify against supplier COA |
| Component 2 | TB-500 / thymosin beta-4-associated research peptide |
| TB-500 Identity Note | TB-500 naming varies across public references. Some references associate it with thymosin beta-4, while FDA safety-risk language specifically identifies TB-500 as thymosin beta-4 fragment LKKTETQ. Confirm exact sequence and molecular data against supplier COA. |
| TB-500 / Thymosin Beta-4 Context | Thymosin beta-4 is commonly discussed in actin-binding, cell migration, angiogenesis, wound-healing, and tissue-repair research contexts. |
| Blend Molecular Formula | Not applicable as a single formula because this is a blend. Use component-specific COA data for final publication. |
| Research Category | Tissue-response research, tendon and ligament models, muscle injury models, wound-healing research, angiogenesis, extracellular matrix research, inflammatory-response markers, and soft-tissue recovery models |
| Research Context | Commonly discussed in controlled research involving tissue repair models, cell migration, collagen organization, tendon and ligament response, muscle injury response, vascular response, and inflammatory-marker documentation. |
| Appearance | White to off-white lyophilized powder, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
BPC-157 & TB-500 blend research is commonly discussed in controlled models involving soft-tissue response, tendon and ligament repair, muscle injury response, wound-healing pathways, angiogenesis, cell migration, extracellular matrix remodeling, inflammatory-response markers, and tissue-recovery documentation.
Tendon & Ligament Models
BPC-157 is commonly discussed in tendon and ligament research involving collagen organization, fibroblast response, ligament healing, and functional tissue-response observations.
Muscle Injury Research
This blend is commonly framed around muscle injury models, myotendinous junction response, tissue remodeling, and controlled recovery-marker documentation.
Wound-Healing Research
TB-500 / thymosin beta-4-associated research is often discussed in wound-healing models involving epithelial migration, wound closure, tissue repair, and cellular movement.
Angiogenesis Context
Both components are commonly discussed in relation to vascular response, endothelial activity, angiogenesis, and tissue-repair pathway observations.
Inflammatory-Response Models
Research models often track inflammatory markers, oxidative-stress context, edema, cytokine-related observations, and post-injury tissue response.
Extracellular Matrix Research
Blend research commonly includes extracellular matrix organization, collagen deposition, fibroblast activity, cell migration, and structural tissue-response documentation.
Research Scope
These applications are provided for educational and research-reference purposes only. Blend research is highly model-dependent, and outcomes may vary based on component identity, ratio, purity, concentration, injury model, route, timing, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Select Reference Vial
Select a total blend vial size to update the concentration, U-100 unit references, and frequency table below.
Quick Reference Summary
| Reference Vial | 10 mg total blend BPC-157 & TB-500 Blend |
|---|---|
| Blend Assumption | Total blend amount is treated as a 1:1 ratio unless otherwise specified. |
| Component Split Reference | 10 mg total blend = 5 mg BPC-157 + 5 mg TB-500. 20 mg total blend = 10 mg BPC-157 + 10 mg TB-500. |
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Primary Concentration | 5 mg/mL total blend |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 5 mg/mL, 1 unit equals 0.05 mg / 50 mcg BPC-157 & TB-500 Blend. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear. Do not shake!
- Label with compound name, total blend amount, assumed component ratio, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Blend Identity Reference | BPC-157 & TB-500 blend, treated here as total blend amount | For this reference, the total blend amount is calculated as a 1:1 ratio of BPC-157 and TB-500 unless a supplier formula or COA states otherwise. |
| BPC-157 Research Context | Model-dependent concentration and endpoint tracking | BPC-157 is commonly discussed in tissue-response, connective-tissue, angiogenesis, inflammatory-marker, gastrointestinal, and recovery-model research contexts. |
| TB-500 Research Context | Model-dependent concentration and endpoint tracking | TB-500-related research is commonly discussed in actin-regulation, cell-migration, tissue-response, connective-tissue, and recovery-model research contexts. |
| Blend-Specific Research Context | No universal blend protocol established | BPC-157 & TB-500 blend references are commonly discussed in public protocol-style research contexts rather than as one standardized published clinical-study format. |
| Calculation Context | 10 mg or 20 mg total blend reference | The tables below convert total blend reference amounts into mL and U-100 unit equivalents. Component-equivalent references are estimated from a 1:1 ratio. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Total Blend Amount | Solution Volume | Final Concentration | Approx. Component Concentration |
|---|---|---|---|
| 10 mg total blend | 2.0 mL | 5 mg/mL total blend | 2.5 mg/mL BPC-157 + 2.5 mg/mL TB-500 |
| 20 mg total blend | 3.0 mL | 6.67 mg/mL total blend | 3.33 mg/mL BPC-157 + 3.33 mg/mL TB-500 |
Research Dosing Amount / Volume Reference
| Total Blend Reference Amount | Component-Equivalent Reference | Volume at 5 mg/mL | U-100 Unit Reference | Approx. References per 10 mg total blend Vial |
|---|---|---|---|---|
| 0.5 mg total blend / 500 mcg | 0.25 mg BPC-157 + 0.25 mg TB-500 | 0.10 mL | 10 units | 20 |
| 1 mg total blend / 1000 mcg | 0.5 mg BPC-157 + 0.5 mg TB-500 | 0.20 mL | 20 units | 10 |
| 2 mg total blend / 2000 mcg | 1 mg BPC-157 + 1 mg TB-500 | 0.40 mL | 40 units | 5 |
| 5 mg total blend / 5000 mcg | 2.5 mg BPC-157 + 2.5 mg TB-500 | 1.00 mL | 100 units | 2 |
| 10 mg total blend / 10000 mcg | 5 mg BPC-157 + 5 mg TB-500 | 2.00 mL | 200 units | 1 |
| 20 mg total blend / 20000 mcg | 10 mg BPC-157 + 10 mg TB-500 | 4.00 mL | 400 units | 0.5 |
Research Frequency / Amount Reference
| Research Window | Frequency | Total Blend Reference Amount | Component-Equivalent Reference | Units / Volume Reference |
|---|---|---|---|---|
| Lower Conversion Reference | Calculation reference only | 0.5 mg total blend | 0.25 mg BPC-157 + 0.25 mg TB-500 | 10 units / 0.10 mL |
| Low-to-Mid Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg total blend | 0.5 mg BPC-157 + 0.5 mg TB-500 | 20 units / 0.20 mL |
| Mid-Range Conversion Example | Public protocol-style reference, not a clinical dosing standard | 2 mg total blend | 1 mg BPC-157 + 1 mg TB-500 | 40 units / 0.40 mL |
| Upper Conversion Example | Calculation reference only | 5 mg total blend | 2.5 mg BPC-157 + 2.5 mg TB-500 | 100 units / 1.00 mL |
| 10 mg Preparation Reference | Preparation-level calculation reference | 10 mg total blend | 5 mg BPC-157 + 5 mg TB-500 | 200 units / 2.00 mL |
| 20 mg Preparation Reference | Preparation-level calculation reference | 20 mg total blend | 10 mg BPC-157 + 10 mg TB-500 | 400 units / 4.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Marker Observation Window | 24–72 hours | May be used for cell-migration, angiogenesis, inflammatory-marker, connective-tissue, actin-regulation, or tissue-response documentation depending on the model. |
| Acute Observation Window | Single session to several days | Used for early response tracking, short-term marker comparison, or preparation-response observation depending on the research design. |
| Short Research Window | 1–4 weeks | May be used for controlled observation involving tissue-response, connective-tissue, inflammatory-marker, or recovery-model endpoints. |
| Standard Protocol-Style Window | 4–8 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 8–12 weeks or longer | Used when longer documentation is needed for tissue-response trends, connective-tissue markers, inflammatory-marker comparison, or follow-up marker tracking. |
| Follow-Up / Washout | 2–8 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. BPC-157 & TB-500 Blend is treated here as a total blend amount with an assumed 1:1 ratio unless otherwise specified. The selector above updates calculations for 10 mg total blend reconstituted with 2.0 mL bacteriostatic water and 20 mg total blend reconstituted with 3.0 mL bacteriostatic water. Component-equivalent references are estimates based on the 1:1 assumption and should be verified against the supplier COA, batch record, or formula record when available. Published study references and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
BPC-157 & TB-500 blend research is commonly discussed in relation to tendon and ligament models, soft-tissue response, muscle injury models, wound-healing observations, angiogenesis context, extracellular matrix remodeling, cell migration, and inflammatory-response documentation.
Study Limitations
Evidence for the combined blend is limited compared with individual component research. BPC-157 and TB-500-related findings are primarily preclinical and should not be treated as established human safety or efficacy conclusions.
Safety Considerations
Research discussion should account for component identity verification, TB-500 sequence confirmation, peptide-related impurities, immunogenicity risk, angiogenesis-related uncertainty, sterility documentation, endotoxin risk, storage conditions, and route-specific uncertainty.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.